Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Assetmark Inc.

Assetmark Inc. lifted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 6.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 46,065 shares of the company’s stock after acquiring an additional 2,852 shares during the period. Assetmark Inc.’s holdings in Apellis Pharmaceuticals were worth $1,329,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Capital Performance Advisors LLP purchased a new position in Apellis Pharmaceuticals in the third quarter valued at approximately $56,000. nVerses Capital LLC grew its position in shares of Apellis Pharmaceuticals by 300.0% in the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after buying an additional 2,100 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Apellis Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after acquiring an additional 781 shares in the last quarter. CWM LLC lifted its position in Apellis Pharmaceuticals by 299.9% in the second quarter. CWM LLC now owns 4,151 shares of the company’s stock valued at $159,000 after acquiring an additional 3,113 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in Apellis Pharmaceuticals by 1,300.8% in the first quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company’s stock valued at $211,000 after acquiring an additional 3,330 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Trading Down 0.7 %

NASDAQ:APLS opened at $28.06 on Friday. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $73.80. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The stock has a fifty day moving average price of $30.45 and a two-hundred day moving average price of $36.51. The stock has a market capitalization of $3.49 billion, a price-to-earnings ratio of -13.82 and a beta of 0.87.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. During the same quarter last year, the business earned ($1.17) EPS. The firm’s revenue for the quarter was up 78.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the transaction, the director now owns 100,000 shares in the company, valued at $3,623,000. This trade represents a 27.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 6.80% of the company’s stock.

Analyst Upgrades and Downgrades

APLS has been the topic of a number of research analyst reports. Wedbush lifted their target price on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Needham & Company LLC reduced their price objective on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. JPMorgan Chase & Co. decreased their price objective on Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $80.00 target price on shares of Apellis Pharmaceuticals in a report on Wednesday, July 31st. Finally, Citigroup lowered their price objective on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Six equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $51.06.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).